Rational Drug Design : HIV Integrase. A process for drug design which bases the design of the drug upon the structure of its protein target. 1.Structural.

Slides:



Advertisements
Similar presentations
HIV-1 protease molecular dynamics of a wild- type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site.
Advertisements

Developing & Benchmarking Large-scale Docking (LSD) Pipeline Niu Huang, 02/17/2004.
Background Goals Methods Results Conclusions Implications.
Mr. Safford’s Biological Sciences.  All enzymes are globular proteins thus spherical in shape  Control biochemical reactions in cells  They have the.
Molecular dynamics refinement and rescoring in WISDOM virtual screenings Gianluca Degliesposti University of Modena and Reggio Emilia Molecular Modelling.
Catalytic Strategies. Basic Catalytic Principles What is meant by the binding energy as it relates to enzyme substrate interactions? –free energy released.
 The active site have a rigid shape.  Only substrates with the matching shape can fit.  The substrate is a key that fits the lock of the active site.
Two Examples of Docking Algorithms With thanks to Maria Teresa Gil Lucientes.
Protein Docking and Interactions Modeling CS 374 Maria Teresa Gil Lucientes November 4, 2004.
Biomolecular Nuclear Magnetic Resonance Spectroscopy BIOCHEMISTRY BEYOND STRUCTURE Protein dynamics from NMR Analytical Biochemistry Comparative Analysis.
An Integrated Approach to Protein-Protein Docking
BL5203: Molecular Recognition & Interaction Lecture 5: Drug Design Methods Ligand-Protein Docking (Part I) Prof. Chen Yu Zong Tel:
Molecular Docking Using GOLD Tommi Suvitaival Seppo Virtanen S Basics for Biosystems of the Cell Fall 2006.
Protein-protein and Protein- ligand Docking The geometric filtering.
Enzymes Review. Learning Outcomes (h) Explain the mode of action of enzymes in terms of an active site, enzyme/substrate complex, lowering of activation.
Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.
ClusPro: an automated docking and discrimination method for the prediction of protein complexes Stephen R. Comeau, David W.Gatchell, Sandor Vajda, and.
y-sa/2.0/. Integrating the Data Prof:Rui Alves Dept Ciencies Mediques Basiques, 1st.
Lecture 4 Web: pollev.com/ucibio Text: To: Type in:
Protein Structure Modelling Many sequences - few structures Homology Modelling - Based on Sequence Similarity with Sequences of Known Structures.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
SimBioSys Inc.© 2004http:// Conformational sampling in protein-ligand complex environment Zsolt Zsoldos SimBioSys Inc., © 2004 Contents:
Altman et al. JACS 2008, Presented By Swati Jain.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Protein Design with Backbone Optimization Brian Kuhlman University of North Carolina at Chapel Hill.
PROTEIN PATTERN DATABASES. PROTEIN SEQUENCES SUPERFAMILY FAMILY DOMAIN MOTIF SITE RESIDUE.
R L R L L L R R L L R R L L water DOCKING SIMULATIONS.
Thermodynamical Stability of Biomolecular Systems: Insights from Molecular Dynamics Free Energy Simulations and Continuum Electrostatics Georgios Archontis.
Chapter 7 Protein Function Ligand --- a molecule bound reversibly by a protein Binding site --- the site on protein to which a ligand binds Induced fit.
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
How NMR is Used for the Study of Biomacromolecules Analytical biochemistry Comparative analysis Interactions between biomolecules Structure determination.
Molecular mechanics Classical physics, treats atoms as spheres Calculations are rapid, even for large molecules Useful for studying conformations Cannot.
HIV-1 PROTEASE Presented by: Aruni karunanyake
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Molecular Modeling in Drug Discovery: an Overview
Annual Health Insurance Premiums And Household Income,
Complete automation in CCP4 What do we need and how to achieve it?
Protease.
The catalytic domain has an RNaseH-type fold and belongs to the superfamily of polynucleotidyl transferases. The active site is comprised of two Asp.
Volume 19, Issue 8, Pages (August 2011)
Virtual Screening.
HIV Integrase Therapeutics
Structure and Function Laura Martin
Bindings of oliver leaf extract (OLE) to HIV-1 fusion protein gp41 John Z.H. Zhang, Department of Chemistry, New York University Recent experimental study.
Rational Drug Design : HIV Integrase
Structure and Function Laura Martin
Structure and Function Laura Martin
Ligand Docking to MHC Class I Molecules
An Integrated Approach to Protein-Protein Docking
AnchorDock: Blind and Flexible Anchor-Driven Peptide Docking
Nicki Harmon, Samantha Hurndon, & Zeb Russo
Large-Scale Conformational Dynamics of the HIV-1 Integrase Core Domain and Its Catalytic Loop Mutants  Matthew C. Lee, Jinxia Deng, James M. Briggs, Yong.
Complementarity of Structure Ensembles in Protein-Protein Binding
Volume 20, Issue 7, Pages (July 2012)
Ligand Binding to the Voltage-Gated Kv1
The Flip Side Chemistry & Biology
Volume 19, Issue 8, Pages (August 2011)
Structural Basis for Specificity in the Poxvirus Topoisomerase
What DNA sequence codes for this chain of amino acids...?
Gregory J. Miller, James H. Hurley  Molecular Cell 
Volume 106, Issue 5, Pages (March 2014)
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Volume 20, Issue 7, Pages (July 2012)
Research Rational Drug Design: A process for drug design which bases the design of the drug upon the structure of its protein target. Structural mapping.
Julia Salas Case Study, CS379a
2.5 - Enzymes.
Presentation transcript:

Rational Drug Design : HIV Integrase

A process for drug design which bases the design of the drug upon the structure of its protein target. 1.Structural mapping of the receptor (protein, P) active site 2.Identification of ligands (L) of complementary shape and appropriate functionality 3.Docking of the ligand to the receptor site - predicting a range of PL complexes with different  G PL values 4.Scoring i.e. ranking  G PL and correlating with experimentally determined properties such as IC 50 values

The catalytic domainhas an RNaseH-type fold and belongs to the superfamily of polynucleotidyl transferases. The active site is comprised of two Asp residues and one Glu, in the typicalD,D(35)E motif, each of which is required for catalysis.

de novo Ligand Design

DCQ acids; DCT acids DKAs Quinolone derived PDPSQL four criteria to conclude that integrase is theinhibitor target: 1. found to be active against recombinant integrase. 2. infected cells treated with the drug must show an accumulation of 2-LTR circles, resulting from the accumulation of viral cDNA and decreased HIV integration into host 3. integrase mutations must be found in drug-resistant viruses 4, the drug should be inactive in biochemical assays against recombinantintegrases bearing the mutations identified in the drug-resistant viruses

Issues in Protein Setup Crystal structure available for Integrase but : I. Limitations of crystal structure:  only catalytic domain  DNA binding not revealed  cystal structure vs. physiologically active structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Protein Setup Crystal structure available for Integrase Catalytic Domain but : I. Crystal reveals trimeric structure II. Position of hydrogens undetermined III. Residues missing or ill-defined IV. Protonation of His undetermined V. Solvation

Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria

Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria Tetrazole pKa=5

Issues in Ligand Design Crystal structure available for CITEP bound to catalytic core but : I. Position of hydrogens undetermined II. Tautomeric structures possible III. Influence of pH IV. Need to limit conformational flexibility based on experimental and theoretical crteria Fixed and planar Based on HF/6-31G * calculations Limited to +/- 45 degrees

Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

Issues in Docking The prediction of the ligand conformation and orientation within a targeted binding site involves: I. Positioning ligand and evaluating quality of binding II. Manually refining ligand position III. Energy minimization (electrostatic, steric, strain and h-bond)

Issues in Scoring The prediction of the optimum ligand conformation and orientation within a targeted binding site involves: I. Posing : Determining the fit of the ligand II. Conformational Searching III. Scoring and Ranking

Results

Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures Ligand Design

Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures Ligand Design

Criterion for Ligand Selection: I. Theoretical and experimental structures II. Fill active site III. Conformational structures Ligand Design

The prediction of the affects of mutations within the binding site on the effects of the ligands involves: I. Identifying possible sights of mutations II. Determining effect of mutations Site Mutations and Drug Resistance

The prediction of the affects of mutations within the binding site on the effects of the ligands involves: I. Identifying possible sights of mutations II. Determining effect of mutations Site Mutations and Drug Resistance

Problem with Protein Flexibility